-
1.发明公开
公开(公告)号：EP2804877A1
公开(公告)日：2014-11-26
申请号：EP13701014.6
申请日：2013-01-17
申请人： VIB vzw , Universiteit Gent , Centre National de la Recherche Scientifique , Université Montpellier 2 , Centre Hospitalier Regional Universitaire De Montpellier , Universität Osnabrück
CPC分类号： A61K38/212 , A61K47/6813 , C07K14/56 , C07K16/2827 , C07K16/2863 , C07K16/2869 , C07K16/2878 , C07K16/32 , C07K2317/22 , C07K2317/569 , C07K2317/622 , C07K2319/31 , C07K2319/74
摘要： This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified α-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified α-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
摘要翻译： 本公开涉及通过α螺旋束细胞因子受体具有降低的活性的经修饰的α-螺旋束细胞因子，其中所述α-螺旋束细胞因子被特异性递送至靶细胞。 优选地，α-螺旋束细胞因子是突变体，更优选是对干扰素受体具有低亲和力的突变型干扰素，其中突变型干扰素被特异性递送至靶细胞。 靶向通过将修饰的α-螺旋束细胞因子与靶向部分（优选抗体）融合来实现。 本公开进一步涉及这种靶向修饰的α-螺旋束细胞因子用于治疗疾病的用途。 优选的实施方案是使用靶向突变型干扰素来治疗疾病，优选病毒性疾病和肿瘤。
-
公开(公告)号：EP3022230A1
公开(公告)日：2016-05-25
申请号：EP14734166.3
申请日：2014-07-01
申请人： VIB VZW , Universiteit Gent , Centre National de la Recherche Scientifique , Université Montpellier 2 , Centre Hospitalier Regional Universitaire De Montpellier
发明人： TAVERNIER, Jan , ZABEAU, Lennart , UZÉ, Gilles , PAUL, Franciane , BORDAT, Yann , GARCIN, Geneviève
摘要： The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
摘要翻译： 本发明涉及融合蛋白，其包含细胞因子拮抗剂和靶向部分，优选抗体或抗体样分子。 在优选的实施方案中，细胞因子拮抗剂是与受体结合但不诱导受体信号传导的修饰的细胞因子。 本发明进一步涉及根据本发明的用于治疗癌症和免疫或炎症相关疾病的融合蛋白。
-
3.发明授权FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES 有权涉及细胞因子与强烈降低的受体结合亲和力的FUSOKINES
公开(公告)号：EP3022305B1
公开(公告)日：2017-11-01
申请号：EP14734831.2
申请日：2014-07-03
申请人： VIB VZW , Universiteit Gent , Centre National de la Recherche Scientifique , Université Montpellier 2 , Centre Hospitalier Regional Universitaire De Montpellier
发明人： TAVERNIER, Jan , BULTINCK, Jennyfer , GERLO, Sarah , UZÉ, Gilles , PAUL, Franciane , BORDAT, Yann
IPC分类号： C12N15/62 , A61K38/19 , A61K38/21 , A61K38/20 , C07K14/56 , C07K14/52 , C07K14/545 , C07K14/525 , C07K14/575
CPC分类号： C07K14/521 , A61P37/04 , C07K14/52 , C07K14/523 , C07K14/525 , C07K14/545 , C07K14/56 , C07K14/5759 , C07K2319/00 , C07K2319/33 , C07K2319/74
摘要： The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
-
4.发明公开FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES 有权FUSOKINE，ZYTOKINE ENTHALTEND，MIT MASSIV REDUZIERTER REZEPTOR-BINDUNGSAFFINITÄT。
公开(公告)号：EP3022305A2
公开(公告)日：2016-05-25
申请号：EP14734831.2
申请日：2014-07-03
申请人： VIB VZW , Universiteit Gent , Centre National de la Recherche Scientifique , Université Montpellier 2 , Centre Hospitalier Regional Universitaire De Montpellier
发明人： TAVERNIER, Jan , BULTINCK, Jennyfer , GERLO, Sarah , UZÉ, Gilles , PAUL, Franciane , BORDAT, Yann
IPC分类号： C12N15/62 , A61K38/19 , A61K38/21 , A61K38/20 , C07K14/56 , C07K14/52 , C07K14/545 , C07K14/525 , C07K14/575
CPC分类号： C07K14/521 , A61P37/04 , C07K14/52 , C07K14/523 , C07K14/525 , C07K14/545 , C07K14/56 , C07K14/5759 , C07K2319/00 , C07K2319/33 , C07K2319/74
摘要： The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
摘要翻译： 本发明涉及包含至少两种细胞因子的融合蛋白，其中至少一种是与其受体或其受体之一具有强烈降低的结合亲和力的修饰的细胞因子。 优选地，两种细胞因子通过接头连接，优选GGS接头连接。 本发明进一步涉及用于治疗疾病的所述融合蛋白。
-
5.发明公开FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES 有权涉及细胞因子与强烈降低的受体结合亲和力的FUSOKINES
公开(公告)号：EP3299466A1
公开(公告)日：2018-03-28
申请号：EP17195867.1
申请日：2014-07-03
申请人： VIB vzw , Universiteit Gent , Centre National de la Recherche Scientifique , Université Montpellier 2 , Centre Hospitalier Régional Universitaire de Montpellier
发明人： TAVERNIER, Jan , BULTINCK, Jennyfer , GERLO, Sarah , UZÉ, Gilles , PAUL, Franciane , BORDAT, Yann
IPC分类号： C12N15/62 , A61K38/19 , A61K38/21 , A61K38/20 , C07K14/56 , C07K14/52 , C07K14/545 , C07K14/525 , C07K14/575
CPC分类号： C07K14/521 , A61P37/04 , C07K14/52 , C07K14/523 , C07K14/525 , C07K14/545 , C07K14/56 , C07K14/5759 , C07K2319/00 , C07K2319/33 , C07K2319/74
摘要： The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
摘要翻译： 本发明涉及包含至少两种细胞因子的融合蛋白，其中至少一种细胞因子是对其受体或其受体之一具有强烈降低的结合亲和力的修饰细胞因子。 优选地，两种细胞因子通过接头连接，优选GGS接头连接。 本发明还涉及用于治疗疾病的所述融合蛋白。
-
公开(公告)号：EP2804877B1
公开(公告)日：2018-08-22
申请号：EP13701014.6
申请日：2013-01-17
申请人： VIB vzw , Universiteit Gent , Centre National de la Recherche Scientifique , Université de Montpellier , Centre Hospitalier Régional Universitaire de Montpellier , Universität Osnabrück
CPC分类号： A61K38/212 , A61K47/6813 , C07K14/56 , C07K16/2827 , C07K16/2863 , C07K16/2869 , C07K16/2878 , C07K16/32 , C07K2317/22 , C07K2317/569 , C07K2317/622 , C07K2319/31 , C07K2319/74
摘要： This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified α-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified α-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
-
公开(公告)号：EP3022230B1
公开(公告)日：2019-11-06
申请号：EP14734166.3
申请日：2014-07-01
申请人： VIB VZW , Universiteit Gent , Centre National de la Recherche Scientifique , Université de Montpellier , Centre Hospitalier Régional Universitaire de Montpellier
-
公开(公告)号：EP3299466B1
公开(公告)日：2019-09-11
申请号：EP17195867.1
申请日：2014-07-03
申请人： VIB VZW , Universiteit Gent , Centre National de la Recherche Scientifique , Université de Montpellier , Centre Hospitalier Régional Universitaire de Montpellier
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.019 秒)
